BetterLife Pharma Advances BETR-001 for Psychiatric Treatment

BetterLife Pharma ( (TSE:BETR) ) has shared an announcement.

BetterLife Pharma has provided a scientific update on BETR-001, a promising compound for treating psychiatric disorders like depression and anxiety. BETR-001 activates the 5HT2A receptor without hallucinogenic effects, unlike other psychedelics, offering a novel treatment paradigm. It avoids cardiac safety issues by not activating the 5HT2B receptor and does not induce tolerance, allowing for daily use. With a composition of matter patent granted, BetterLife plans to start human trials in 2026, potentially impacting the treatment landscape for psychiatric disorders.

Spark’s Take on TSE:BETR Stock

According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

To see Spark’s full report on TSE:BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic neuroplastogen, and BETR-002, based on honokiol, for treating various psychiatric and neurological disorders.

Average Trading Volume: 54,828

Technical Sentiment Signal: Sell

Current Market Cap: C$11.01M

For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.